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Aim: Pyrazinamide (PZA) is a first-line key agent in the effective treatment of tuberculosis
(TB), including PZA susceptible multidrug-resistant tuberculosis (MDR-TB). Occasionally, TB
patients might have mixed infections with both drug-sensitive and -resistant strains. This
is termed heteroresistance. If 10% of the bacterial population is resistant to PZA, there is an
increased risk for poor treatment outcome. The aim of this study is to evaluate the ability of
the three established drug susceptibility testing (DST) techniques – BACTEC MGIT 960,
Wayne’s pyrazinamidase test and Sanger sequencing of the pncA gene – to detect 10%
PZA heteroresistance.
Methods: Mixed cultures of the fully drug susceptible Mycobacterium tuberculosis H37Rv ref-
erence strain and two laboratory-generated isogenic H37Rv mutants (with C475G and
T254C pncA mutations, respectively) were made in proportions of 100%, 10%, 5% and 1%
of the PZA-resistant (PZA-R) strain. Corresponding mixed cultures were also made using
one drug-susceptible and one PZA-resistant MDR clinical isolate with the T62G pncA muta-
tion, both belonging to one specific MIRU cluster. Additional mixes of 50%, 75%, 90% and
99% of the PZA-R strains were prepared for theWayne’s test. Tests were for all methods per-
formed in duplicates at two separate occasions.
Results: Using the MGIT system, the in vitro-generated PZA-R strains were generally
detected at a 5% proportion while the clinical PZA-R isolate only was detected at the critical
10% proportion, except for one test occasion. Sanger sequencing was unable to detect 10%
PZA heteroresistance. Wayne’s test also failed to detect the critical level of 10% PZA resis-
tance; instead it displayed misguiding results determining highly resistant samples as sus-
ceptible.
Conclusion: Heteroresistance is caused by present drug-resistance development and/or dual
infections with one resistant and one susceptible strain. Mixed infections with resistant
strains may occur in up to 20% of all TB cases in high burden areas, according to limited
data. This study showed that only the phenotypic BACTEC MGIT system was capable in
determining the critical proportion of 10% PZA resistance, whereas neither the Sanger
nor the Wayne’s test were successful in this respect. This indicates a need for diagnostic
tools with increased sensitivity to determine heteroresistance in M. tuberculosis.
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